The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to ...

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum ...